In addition to COVID-19-related research targeting ACE2 for aiding diagnosis, developing therapeutics, and monitoring treatment response, reduced ACE2 activity has been detected in many cancers when compared with healthy individuals [154]. This evidence concerns the gene ACE2 and COVID-19.